Genomics Launches the Mystra AI Platform, Adopted by Industry Giants and Up-and-Coming Biotechs
PR Newswire
LONDON, June 2, 2026
New conversational AI platform leverages the world's largest human genetics database to power target discovery and validation. Mystra AI is the market-leading agent, accessible to all scientists in Research & Development and Business Development & Licensing.95% of drug candidates in clinical trials fail. Targets with human genetic support are 2.6 times more likely to succeed in clinical trials. Mystra AI leverages the world's largest and most diverse genotype-phenotype database and best-in-class proprietary tools and methodologies to help predict which drug candidates will succeed, potentially saving billions. The platform provides scientists with full control and transparency of the R&D drug target discovery and validation process using genetic insights. LONDON, June 2, 2026 /PRNewswire/ -- Genomics, a science-led Techbio company using large-scale genetic information to develop innovative precision healthcare tools and to accelerate drug discovery and development, has today announced the launch of Mystra AI, the best-in-class human genetics agentic AI platform designed to supercharge drug target discovery and validation.
